Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114381 | 0.88 | HDAC1 (0.41) | TRPM8CYP2D6 | |
| SCHEMBL1114358 | 0.86 | HDAC3 (0.41) | ATM | |
| SCHEMBL3240112 | 0.86 | MEN1 (0.40) | SLC6A9KCNH2TRPM8ATMSLC6A5 | |
| SCHEMBL1114378 | 0.84 | LPAR1 (0.38) | PPARGPPARA | |
| SCHEMBL3247272 | 0.83 | RIPK1 (0.34) | SLC6A9KCNH2PPARGPPARAS1PR1 | |
| SCHEMBL1114600 | 0.78 | CASP3 (0.44) | TRPM8 | |
| SCHEMBL1114312 | 0.78 | HDAC1 (0.41) | CYP2D6 | |
| SCHEMBL13447662 | 0.77 | TP53 (0.43) | — | |
| SCHEMBL1114142 | 0.76 | HDAC3 (0.43) | TRPM8ATMSCN10AS1PR1 | |
| SCHEMBL1114740 | 0.76 | TRPM8 (0.42) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278879-B1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | PATH DRUG SOLUTIONS (US) | 2016-06-15 | — | — | EP | claimed |
| US-8207205-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-06-26 | — | — | US | claimed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | claimed |
| EP-2278879-B1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | PATH DRUG SOLUTIONS (US) | 2016-06-15 | — | — | EP | disclosed |
| US-8796321-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | PATH DRUG SOLUTIONS (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796321-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | PATH DRUG SOLUTIONS (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796321-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | PATH DRUG SOLUTIONS (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2012-10-18 | — | — | US | disclosed |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2012-10-18 | — | — | US | disclosed |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2012-10-18 | — | — | US | disclosed |
| US-8207205-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| WO-2009131957-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | SLC6A9 528/4885KCNH2 362/4885TRPM8 1546/4885 |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | CFTR, PKD1, PKD2 | SLC6A9 882/4885KCNH2 314/4885TRPM8 1438/4885 |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | CFTR, PKD1, PKD2 | SLC6A9 882/4885KCNH2 314/4885TRPM8 1438/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | SLC6A9 528/4885KCNH2 362/4885TRPM8 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.